Paper offers a lesson that more data doesn't always mean more learnings, says safety guru

When the US Food and Drug Administration (FDA) found that it was in danger of drowning in the volume of safety reports being submitted relating to approved therapies, the agency brought in Transcelerate BioPharma to help.

This US non-profit, which brings together members of the research and development community to help find solutions that lead to better, safer medicines reaching patients, brought together a pharma consortium to take on pharmacovigilance as an area of high priority.

Peter Verdu (pictured above), former head of patient safety at Belgian drugmaker UCB (Euronext: UCB) and now a consultant with PVMD2, was one of five authors of a paper subsequently published on the issue.